NEW YORK (360Dx) – Bühlmann Laboratories said Thursday that it has received US Food and Drug Administration clearance for its fCal ELISA assay, which uses the measurement of calprotectin protein in human stool to diagnose inflammatory bowel disease, more specifically Crohn’s disease and ulcerative colitis. The assay can also be used in conjunction with other laboratory and clinical findings to differentiate IBD from irritable bowel syndrome, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.